FIDELIO-DKD (FI nerenone in reducing ki D n E y fai L ure and d I sease pr O gression in D iabetic K idney D isease) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...

Detailed results from the phase III FIDELIO-DKD study demonstrated that the investigational drug finerenone slowed the progression of chronic kidney disease (CKD) in patients with CKD and type 2 ...

Bayer’s phase III study FIDELIO-DKD evaluating the efficacy and safety of finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes ...

(RTTNews) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L) announced that the Phase III study FIDELIO-DKD, which is evaluating the efficacy and safety of finerenone versus placebo when added to standard of care ...

Canadian officials ‌will meet their Mexican and U.S. ⁠counterparts on July 1 for the first trilateral meeting ‌to ⁠review the U.S.-Canada-Mexico trade agreement, CTV ⁠News reported on ⁠Saturday.

* BAYER - FINERENONE REDUCED COMBINED PRIMARY ENDPOINT OF RISK OF CHRONIC KIDNEY DISEASE PROGRESSION, KIDNEY FAILURE/KIDNEY DEATH VERSUS PLACEBO WHEN ADDED TO STANDARD OF CARE Source text for Eikon: ...